259 related articles for article (PubMed ID: 35703731)
1. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
Lagoubi Y; Sfar MT; Gomez JA
Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
[TBL] [Abstract][Full Text] [Related]
4. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
Varghese L; Talbot L; Govender A; Zhang XH; Mungall BA
Appl Health Econ Health Policy; 2018 Jun; 16(3):331-345. PubMed ID: 29633160
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable
Lu CY; Chung CH; Huang LM; Kruger E; Tan SC; Zhang XH; Chiu NC
Cost Eff Resour Alloc; 2020; 18():30. PubMed ID: 32874139
[TBL] [Abstract][Full Text] [Related]
6. Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil.
Gomez JA; Lopes de Abreu AJ; Caceres DC; Nieto J; Ortega-Barria E
Pediatr Infect Dis J; 2019 Oct; 38(10):e260-e265. PubMed ID: 31568144
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.
Gomez JA; Tirado JC; Navarro Rojas AA; Castrejon Alba MM; Topachevskyi O
BMC Public Health; 2013 Oct; 13():1025. PubMed ID: 24171921
[TBL] [Abstract][Full Text] [Related]
8. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease.
Izurieta P; Nieto Guevara J
Hum Vaccin Immunother; 2022 Dec; 18(1):1872341. PubMed ID: 33605846
[TBL] [Abstract][Full Text] [Related]
9. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
[TBL] [Abstract][Full Text] [Related]
10. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
De Wals P; Black S; Borrow R; Pearce D
Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
[TBL] [Abstract][Full Text] [Related]
12. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children.
Marijam A; Olbrecht J; Ozakay A; Eken V; Meszaros K
Value Health Reg Issues; 2019 Sep; 19():34-44. PubMed ID: 30776766
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia.
Wang XJ; Saha A; Zhang XH
Cost Eff Resour Alloc; 2017; 15():17. PubMed ID: 28852326
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
[TBL] [Abstract][Full Text] [Related]
18. 10-Valent pneumococcal non-typeable
Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
[TBL] [Abstract][Full Text] [Related]
19. 10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.
Plosker GL
Paediatr Drugs; 2014 Oct; 16(5):425-44. PubMed ID: 25192686
[TBL] [Abstract][Full Text] [Related]
20. Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme.
Aljunid S; Maimaiti N; Ahmed Z; Muhammad Nur A; Md Isa Z; Azmi S; Sulong S
Value Health Reg Issues; 2014 May; 3():146-155. PubMed ID: 29702920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
